Seeking Alpha

ProQR's sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10

|About: ProQR Therapeutics N.V. (PRQR)|By:, SA News Editor

The FDA grants Rare Pediatric Disease designation for ProQR Therapeutics' (NASDAQ:PRQR) sepofarsen for the treatment of Leber congenital amaurosis type 10 (LCA10).

Rare Pediatric Disease designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be use for accelerated approval of a future application or it can be sold to a third party.

Shares are down 12% after hours in response to its $50M equity offering. Price, volume and terms have yet to be announced.

Try Seeking Alpha PREMIUM for unlimited analysis on PRQR